These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6419536)

  • 1. Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids.
    Zaccara G; Boncinelli L; Paganini M; Campostrini R; Arnetoli G; Zappoli R
    Acta Neurol Scand; 1983 Oct; 68(4):241-7. PubMed ID: 6419536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-chain organic acidemia and Reye's syndrome.
    Trauner DA; Nyhan WL; Sweetman L
    Neurology; 1975 Mar; 25(3):296-8. PubMed ID: 1167641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alterations of the state of consciousness induced by valproic acid: 6 case reports].
    Campostrini R; Paganini M; Boncinelli L; Zaccara G; Arnetoli G; Zappoli R
    Riv Patol Nerv Ment; 1983; 104(1):23-34. PubMed ID: 6431599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reye-like syndrome associated with valproic acid.
    Sugimoto T; Nishida N; Yasuhara A; Ono A; Sakane Y; Matsumura T
    Brain Dev; 1983; 5(3):334-7. PubMed ID: 6412580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.
    Zaccara G; Campostrini R; Paganini M; Moroni F; Valenza T; Targioni G; Arnetoli G; Zappoli R; Baruzzi A
    Neurology; 1984 Nov; 34(11):1519-21. PubMed ID: 6436733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Encephalopathies caused by valproate].
    Göbel R; Görtzen A; Bräunig P
    Fortschr Neurol Psychiatr; 1999 Jan; 67(1):7-11. PubMed ID: 10065384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EEG correlations with biochemical abnormalities in Reye syndrome.
    Trauner DA; Stockard JJ; Sweetman L
    Arch Neurol; 1977 Feb; 34(2):116-8. PubMed ID: 836179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation of hepatic ammonia metabolism after chronic valproate administration in epileptics treated with phenytoin.
    Marescaux C; Warter JM; Brandt C; Rumbach L; Micheletti G; Chabrier G; Imler M
    Eur Neurol; 1985; 24(3):191-5. PubMed ID: 3922765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
    Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
    Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
    Hamer HM; Knake S; Schomburg U; Rosenow F
    Neurology; 2000 Jan; 54(1):230-2. PubMed ID: 10636156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
    Mehndiratta MM; Mehndiratta P; Phul P; Garg S
    J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.